ClinicalTrials.gg
CompletedNCT05595642ARNASAUpdated Oct 28, 2026Results posted

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

A Phase 3 interventional study of Astegolimab and Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Hoffmann-La Roche. Completed at 348 sites in 36 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Oct 28, 2026Now CompletedResults posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,380
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche — 1 open to participants now, 2 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Hoffmann-La Roche.

Started
2022
the only one that year
Phase 3
2 of 10
none open now
Registered
5th of 10
by date

Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, this one is the only one that started in 2022, is one of 2 in phase 3, and was the 5th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis for ≥ 12 months
  • History of frequent exacerbations, defined as having had 2 or more moderate or severe COPD exacerbations within 12 months prior to screening
  • Post-bronchodilator ≥ 20% and \< 80% of predicted at screening
  • Post-bronchodilator FEV1/FVC \< 0.70 at screening
  • Modified Medical Research Council (dyspnea scale) (mMRC) score ≥ 2
  • Current tobacco smoker or former smoker with a history of smoking ≥ 10 pack-years
  • On optimized COPD maintenance therapy as defined below for ≥ 12 months prior to screening, and stable on current therapy for at least 4 weeks prior to screening: Inhaled (ICS) plus long-acting beta-agonist (LABA), Long-acting muscarinic antagonist (LAMA) plus LABA, ICS plus LAMA plus LABA
  • Chest X-ray or computed tomography (CT) scan within 6 months prior to screening or chest X-ray during the screening period that confirms the absence of lung disease besides COPD

Exclusion criteria

Exclusion Criteria

  • Current documented diagnosis of asthma
  • History of pulmonary disease other than
  • Diagnosis of 1-antitrypsin deficiency
  • History of long-term treatment with oxygen at > 4.0 liters/minute
  • Lung volume reduction surgery or procedure within 12 months prior to screening
  • Individuals participating in, or scheduled for, an intensive COPD rehabilitation program (participants who are in the maintenance phase of a rehabilitation program are eligible)
  • History of lung transplant
  • Any infection that resulted in hospital admission for ≥ 24 hours and/or treatment with oral, IV, or IM antibiotics within 4 weeks prior to or during screening
  • Upper or lower respiratory tract infection within 4 weeks prior to or during screening
  • Treatment with oral, IV, or IM within 4 weeks prior to initiation of study drug
  • Initiation of or change in non-biologic immunomodulatory or therapy within 3 months prior to screening
  • Unstable cardiac disease, myocardial infarction, or Class III or IV heart failure within 12 months prior to screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,380 participants (actual)

Study arms

  • Experimental
    Astegolimab SC Q2W

    Participants will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W)

    Drug: Astegolimab

  • Experimental
    Astegolimab SC Q4W

    Participants will receive alternating SC astegolimab and placebo Q2W, thus receiving SC astegolimab Q4W.

    Drug: Astegolimab

  • Placebo comparator
    Placebo SC Q2W

    Participants will receive SC placebo Q2W

    Drug: Placebo

Interventions

  • Participants will receive SC astegolimab Q2W or Q4W

  • DrugPlacebo

    Participants will receive SC placebo Q2W

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-week Treatment Period

    A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, intravenous \[IV\], or intramuscular \[IM\]) at a dose of \> 10 milligrams per day (mg/day) prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted AER was estimated as the total number of exacerbations observed over the treatment period divided by the total participant-years at risk (participant-years = date of first study drug administration to completion or discontinuation during the double-blind treatment period divided by 365.25 days). The adjusted AER was estimated using negative binomial regression. Adjusted rate values have been reported. A method of dispersion was not specified in the SAP.

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-week Treatment Period in Participants With Low Baseline Blood Eosinophil Level (<300 Cells Per Microliter [Cells/µL])

    A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, intravenous \[IV\], or intramuscular \[IM\]) at a dose of \> 10 milligrams per day (mg/day) prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted AER was estimated as the total number of exacerbations observed over the treatment period divided by the total participant-years at risk (participant-years = date of first study drug administration to completion or discontinuation during the double-blind treatment period divided by 365.25 days). The adjusted AER was estimated using negative binomial regression. Adjusted rate values have been reported A method of dispersion was not specified in the SAP.

    Time frame: Up to 52 weeks

  2. Time to First Moderate or Severe COPD Exacerbation During the 52-week Treatment Period

    Time to first moderate or severe COPD exacerbation was defined as the time from the first administration of study drug to the first incidence of moderate or severe COPD exacerbation event during the 52-week treatment period. A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥3 days) with systemic corticosteroids (oral, IV, or IM) at a dose of \>10 mg/day prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. Kaplan-Meier (K-M) method was used to estimate the median time.

    Time frame: Up to 52 weeks

  3. Absolute Change From Baseline in Health-related Quality-of-life (HRQoL) at Week 52, as Assessed Through the Saint George's Respiratory Questionnaire-COPD (SGRQ-C) Total Score

    SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL. Adjusted mean of change from baseline (CFB) is reported here.

    Time frame: At Week 52

  4. Absolute Change From Baseline in Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (Liters) at Week 52

    Post-bronchodilator FEV1 was defined as the FEV1 value measured with spirometry 20-30 minutes after bronchodilator use. Maximal bronchodilation was achieved via administration of either albuterol (90 micrograms \[µg\] metered dose) or salbutamol (100 µg metered dose), with or without a spacer device, up to a maximum of 4 inhalations. Adjusted mean of CFB is reported here.

    Time frame: At Week 52

  5. Absolute Change From Baseline in Evaluating Respiratory Symptoms in COPD (E-RS: COPD) Total Score at Week 52

    The EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) is a 14-item participant-reported instrument used to assess the frequency, severity, and duration of COPD exacerbations using a daily electronic diary (eDiary). It includes four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (tired or weak, sleep disturbance, and scared or worried; 3 items). The E-RS:COPD is an 11-item subset of the EXACT designed to assess the severity of cardinal respiratory symptoms of COPD, including breathlessness, cough, sputum, chest congestion, and chest tightness. It consists of three subscales: RS-Breathlessness, RS-Cough \& Sputum, and RS-Chest Symptoms. Items are scored on 5- or 6-point Likert scales, and the total score is calculated by summing the item scores, ranging from 0 (no impact) to 40 (high impact), with higher scores indicating greater symptom severity. Adjusted mean of CFB is reported here.

    Time frame: At Week 52

  6. Percentage of Participants With Improvement in HRQoL at Week 52, as Assessed by SGRQ-C

    Percentage of participants with SGRQ-C improvement was defined as the percentage of participants with an absolute decrease from baseline of ≥4 points in SGRQ-C total score. SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL.

    Time frame: At Week 52

  7. Annualized Rate of Severe COPD Exacerbations Over the 52-week Treatment Period

    A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted AER was estimated as the total number of exacerbations observed over the treatment period divided by the total participant-years at risk (participant-years = date of first study drug administration to completion or discontinuation during the double-blind treatment period divided by 365.25 days). The adjusted AER was estimated using negative binomial regression. Adjusted rate values have been reported. A method of dispersion was not specified in the SAP.

    Time frame: Up to 52 weeks

  8. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Including Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)

    An AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability or incapacity; is a congenital anomaly or birth defect; is medically significant. An AESI was defined as any of the following: cases of potential drug-induced liver injury; suspected transmission of an infectious agent by a study treatment; major adverse cardiovascular events (MACE); anaphylaxis, anaphylactoid, and hypersensitivity reactions.

    Time frame: Up to a maximum of 62 weeks

  9. Number of Participants Who Died or Discontinued Study Due to TEAEs

    An AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. Participants who died or discontinued the study due to TEAEs will be reported here.

    Time frame: Up to a maximum of 62 weeks

  10. Serum Concentration of Astegolimab

    Time frame: Up to a maximum of 62 weeks

  11. Number of Participants With Anti-drug Antibodies (ADAs) to Astegolimab

    Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following astegolimab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response).

    Time frame: Up to a maximum of 62 weeks

07

Results

Posted Oct 28, 2026

Participant flow

A total of 1382 participants with chronic obstructive pulmonary disease (COPD) who were former or current smokers and had a history of frequent exacerbations took part in the study at 319 investigative sites across 35 countries. The study is still ongoing; data for an additional Japan extension cohort that was not part of the primary analysis will be submitted upon final study completion.

Participant flow — Overall Study
MilestoneAstegolimab Q2WAstegolimab Q4WPlacebo
Started460461459
Safety-evaluable (se) population464462449
Completed404411404
Not completed565055
Withdrew: Adverse event835
Withdrew: Death111814
Withdrew: Lost to follow-up236
Withdrew: Reason not specified022
Withdrew: Physician decision323
Withdrew: Protocol violation203
Withdrew: Withdrawal by subject302222

Outcome measures

PrimaryAnnualized Rate of Moderate and Severe COPD Exacerbations Over the 52-week Treatment Period

A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, intravenous \[IV\], or intramuscular \[IM\]) at a dose of \> 10 milligrams per day (mg/day) prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted AER was estimated as the total number of exacerbations observed over the treatment period divided by the total participant-years at risk (participant-years = date of first study drug administration to completion or discontinuation during the double-blind treatment period divided by 365.25 days). The adjusted AER was estimated using negative binomial regression. Adjusted rate values have been reported. A method of dispersion was not specified in the SAP.

Time frame:
Up to 52 weeks
Reported as:
Number · Exacerbation per participant year
Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-week Treatment Period
Exacerbation per participant yearAstegolimab Q2WAstegolimab Q4WPlacebo
Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-week Treatment Period1.000 (0.722 to 1.011)0.963 (0.695 to 0.975)1.171
Statistical analysis
  • Astegolimab Q2W vs Placebo · Negative Binomial Regression Model · p = 0.0675 · Adjusted rate ratio: 0.855 · 95% CI 0.722 to 1.011
  • Astegolimab Q4W vs Placebo · Negative Binomial Regression Model · p = 0.0239 · Adjusted rate ratio: 0.823 · 95% CI 0.695 to 0.975
SecondaryAnnualized Rate of Moderate and Severe COPD Exacerbations Over the 52-week Treatment Period in Participants With Low Baseline Blood Eosinophil Level (<300 Cells Per Microliter [Cells/µL])

A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, intravenous \[IV\], or intramuscular \[IM\]) at a dose of \> 10 milligrams per day (mg/day) prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted AER was estimated as the total number of exacerbations observed over the treatment period divided by the total participant-years at risk (participant-years = date of first study drug administration to completion or discontinuation during the double-blind treatment period divided by 365.25 days). The adjusted AER was estimated using negative binomial regression. Adjusted rate values have been reported A method of dispersion was not specified in the SAP.

Time frame:
Up to 52 weeks
Reported as:
Number · Exacerbation per participant-year
Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-week Treatment Period in Participants With Low Baseline Blood Eosinophil Level (<300 Cells Per Microliter [Cells/µL])
Exacerbation per participant-yearAstegolimab Q2WAstegolimab Q4WPlacebo
Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-week Treatment Period in Participants With Low Baseline Blood Eosinophil Level (<300 Cells Per Microliter [Cells/µL])0.989 (0.730 to 1.042)0.969 (0.715 to 1.022)1.134
Statistical analysis
  • Astegolimab Q2W vs Placebo · Negative Binomial Regression Model · p = 0.1321 · Adjusted rate ratio: 0.872 · 95% CI 0.730 to 1.042
  • Astegolimab Q4W vs Placebo · Negative Binomial Regression Model · p = 0.0846 · Adjusted rate ratio: 0.854 · 95% CI 0.715 to 1.022
SecondaryTime to First Moderate or Severe COPD Exacerbation During the 52-week Treatment Period

Time to first moderate or severe COPD exacerbation was defined as the time from the first administration of study drug to the first incidence of moderate or severe COPD exacerbation event during the 52-week treatment period. A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥3 days) with systemic corticosteroids (oral, IV, or IM) at a dose of \>10 mg/day prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. Kaplan-Meier (K-M) method was used to estimate the median time.

Time frame:
Up to 52 weeks
Reported as:
Median · weeks
Time to First Moderate or Severe COPD Exacerbation During the 52-week Treatment Period
weeksAstegolimab Q2WAstegolimab Q4WPlacebo
Time to First Moderate or Severe COPD Exacerbation During the 52-week Treatment Period47.1 (39.6 to NA)45.6 (39.3 to NA)38.7 (33.9 to 47.7)
Statistical analysis
  • Astegolimab Q2W vs Placebo · Log Rank · p = 0.2484 · Hazard ratio (hr): 0.90 · 95% CI 0.75 to 1.08
  • Astegolimab Q4W vs Placebo · Log Rank · p = 0.2316 · Hazard ratio (hr): 0.90 · 95% CI 0.75 to 1.07
SecondaryAbsolute Change From Baseline in Health-related Quality-of-life (HRQoL) at Week 52, as Assessed Through the Saint George's Respiratory Questionnaire-COPD (SGRQ-C) Total Score

SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL. Adjusted mean of change from baseline (CFB) is reported here.

Time frame:
At Week 52
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Health-related Quality-of-life (HRQoL) at Week 52, as Assessed Through the Saint George's Respiratory Questionnaire-COPD (SGRQ-C) Total Score
score on a scaleAstegolimab Q2WAstegolimab Q4WPlacebo
Absolute Change From Baseline in Health-related Quality-of-life (HRQoL) at Week 52, as Assessed Through the Saint George's Respiratory Questionnaire-COPD (SGRQ-C) Total Score-7.374 ± 0.888-7.644 ± 0.875-6.601 ± 0.883
Statistical analysis
  • Astegolimab Q2W vs Placebo · Mixed Model for Repeated Measures (MMRM) · p = 0.5373 · Difference in adjusted means of cfb: -0.773 · 95% CI -3.230 to 1.684
  • Astegolimab Q4W vs Placebo · MMRM · p = 0.4015 · Difference in adjusted means of cfb: -1.044 · 95% CI -3.483 to 1.396
SecondaryAbsolute Change From Baseline in Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (Liters) at Week 52

Post-bronchodilator FEV1 was defined as the FEV1 value measured with spirometry 20-30 minutes after bronchodilator use. Maximal bronchodilation was achieved via administration of either albuterol (90 micrograms \[µg\] metered dose) or salbutamol (100 µg metered dose), with or without a spacer device, up to a maximum of 4 inhalations. Adjusted mean of CFB is reported here.

Time frame:
At Week 52
Reported as:
Mean · liters
Absolute Change From Baseline in Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (Liters) at Week 52
litersAstegolimab Q2WAstegolimab Q4WPlacebo
Absolute Change From Baseline in Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (Liters) at Week 52-0.008 ± 0.011-0.025 ± 0.011-0.022 ± 0.011
Statistical analysis
  • Astegolimab Q2W vs Placebo · MMRM · p = 0.3748 · Difference in adjusted means of cfb: 0.014 · 95% CI -0.017 to 0.046
  • Astegolimab Q4W vs Placebo · MMRM · p = 0.8742 · Difference in adjusted means of cfb: -0.003 · 95% CI -0.034 to 0.029
SecondaryAbsolute Change From Baseline in Evaluating Respiratory Symptoms in COPD (E-RS: COPD) Total Score at Week 52

The EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) is a 14-item participant-reported instrument used to assess the frequency, severity, and duration of COPD exacerbations using a daily electronic diary (eDiary). It includes four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (tired or weak, sleep disturbance, and scared or worried; 3 items). The E-RS:COPD is an 11-item subset of the EXACT designed to assess the severity of cardinal respiratory symptoms of COPD, including breathlessness, cough, sputum, chest congestion, and chest tightness. It consists of three subscales: RS-Breathlessness, RS-Cough \& Sputum, and RS-Chest Symptoms. Items are scored on 5- or 6-point Likert scales, and the total score is calculated by summing the item scores, ranging from 0 (no impact) to 40 (high impact), with higher scores indicating greater symptom severity. Adjusted mean of CFB is reported here.

Time frame:
At Week 52
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Evaluating Respiratory Symptoms in COPD (E-RS: COPD) Total Score at Week 52
score on a scaleAstegolimab Q2WAstegolimab Q4WPlacebo
Absolute Change From Baseline in Evaluating Respiratory Symptoms in COPD (E-RS: COPD) Total Score at Week 52-2.281 ± 0.283-1.880 ± 0.277-2.230 ± 0.280
Statistical analysis
  • Astegolimab Q2W vs Placebo · MMRM · p = 0.8985 · Difference in adjusted means of cfb: -0.051 · 95% CI -0.831 to 0.729
  • Astegolimab Q4W vs Placebo · MMRM · p = 0.3745 · Difference in adjusted means of cfb: 0.350 · 95% CI -0.423 to 1.123
SecondaryPercentage of Participants With Improvement in HRQoL at Week 52, as Assessed by SGRQ-C

Percentage of participants with SGRQ-C improvement was defined as the percentage of participants with an absolute decrease from baseline of ≥4 points in SGRQ-C total score. SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement in HRQoL at Week 52, as Assessed by SGRQ-C
percentage of participantsAstegolimab Q2WAstegolimab Q4WPlacebo
Percentage of Participants With Improvement in HRQoL at Week 52, as Assessed by SGRQ-C58.553.748.5
Statistical analysis
  • Astegolimab Q2W vs Placebo · Negative binomial regression · p = 0.0037 · Odds ratio (or): 1.49 · 95% CI 1.14 to 1.96
  • Astegolimab Q4W vs Placebo · Negative binomial regression · p = 0.1332 · Odds ratio (or): 1.23 · 95% CI 0.94 to 1.61
SecondaryAnnualized Rate of Severe COPD Exacerbations Over the 52-week Treatment Period

A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted AER was estimated as the total number of exacerbations observed over the treatment period divided by the total participant-years at risk (participant-years = date of first study drug administration to completion or discontinuation during the double-blind treatment period divided by 365.25 days). The adjusted AER was estimated using negative binomial regression. Adjusted rate values have been reported. A method of dispersion was not specified in the SAP.

Time frame:
Up to 52 weeks
Reported as:
Number · Exacerbation per participant-year
Annualized Rate of Severe COPD Exacerbations Over the 52-week Treatment Period
Exacerbation per participant-yearAstegolimab Q2WAstegolimab Q4WPlacebo
Annualized Rate of Severe COPD Exacerbations Over the 52-week Treatment Period0.136 (0.472 to 0.948)0.168 (0.588 to 1.160)0.204
Statistical analysis
  • Astegolimab Q2W vs Placebo · Negative binomial regression · p = 0.0238 · Adjusted rate ratio: 0.669 · 95% CI 0.472 to 0.948
  • Astegolimab Q4W vs Placebo · Negative binomial regression · p = 0.2705 · Adjusted rate ratio: 0.826 · 95% CI 0.588 to 1.160
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Including Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)

An AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability or incapacity; is a congenital anomaly or birth defect; is medically significant. An AESI was defined as any of the following: cases of potential drug-induced liver injury; suspected transmission of an infectious agent by a study treatment; major adverse cardiovascular events (MACE); anaphylaxis, anaphylactoid, and hypersensitivity reactions.

Time frame:
Up to a maximum of 62 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants Who Died or Discontinued Study Due to TEAEs

An AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. Participants who died or discontinued the study due to TEAEs will be reported here.

Time frame:
Up to a maximum of 62 weeks

Results for this outcome have not been posted.

SecondarySerum Concentration of Astegolimab
Time frame:
Up to a maximum of 62 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Anti-drug Antibodies (ADAs) to Astegolimab

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following astegolimab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response).

Time frame:
Up to a maximum of 62 weeks

Results for this outcome have not been posted.

Adverse events

Collected over Up to 62 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Astegolimab Q2W11/464 (2.4%)113/464 (24.4%)243/464 (52.4%)
Astegolimab Q4W18/462 (3.9%)124/462 (26.8%)275/462 (59.5%)
Placebo15/449 (3.3%)107/449 (23.8%)267/449 (59.5%)
Most frequent serious events
Showing 10 of 178
Most frequent serious events
EventAstegolimab Q2WAstegolimab Q4WPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders62/46468/46267/449
PneumoniaInfections and infestations17/46414/46218/449
COVID-19Infections and infestations3/4641/4626/449
Infective exacerbation of chronic obstructive airways diseaseInfections and infestations3/4641/4625/449
Respiratory failureRespiratory, thoracic and mediastinal disorders2/4643/4625/449
Lower respiratory tract infectionInfections and infestations2/4644/4624/449
Cerebral infarctionNervous system disorders0/4644/4620/449
Cardiac failureCardiac disorders0/4640/4623/449
DeathGeneral disorders and administration site conditions2/4643/4623/449
InfluenzaInfections and infestations2/4642/4623/449
Most frequent other events
Most frequent other events
EventAstegolimab Q2WAstegolimab Q4WPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders178/464208/462198/449
Upper respiratory tract infectionInfections and infestations51/46450/46245/449
NasopharyngitisInfections and infestations33/46443/46229/449
DiarrhoeaGastrointestinal disorders18/46412/46228/449
DyspnoeaRespiratory, thoracic and mediastinal disorders18/46419/46224/449
HeadacheNervous system disorders12/46418/46223/449

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants, whether or not the participant received the assigned treatment, with participants grouped according to the treatment assigned at randomization.

Age, Continuous
Age, Continuous(years)Astegolimab Q2WAstegolimab Q4WPlaceboTotal
Mean66.8 ± 7.566.6 ± 7.466.8 ± 6.966.7 ± 7.3
Sex: Female, Male
Sex: Female, Male(Participants)Astegolimab Q2WAstegolimab Q4WPlaceboTotal
Female172164156492
Male288297303888
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Astegolimab Q2WAstegolimab Q4WPlaceboTotal
Hispanic or Latino666771204
Not Hispanic or Latino3843783711133
Unknown or Not Reported10161743
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Astegolimab Q2WAstegolimab Q4WPlaceboTotal
American Indian or Alaska Native44311
Asian106101115322
Native Hawaiian or Other Pacific Islander4015
Black or African American20352176
White320310311941
More than one race1023
Unknown or Not Reported511622
08

Study locations

348 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS
    Dothan, Alabama 36305, United States
  • Pulmonary Associates PA
    Glendale, Arizona 85306-4669, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - Tucson
    Tucson, Arizona 85741-3118, United States
  • Kern Research
    Bakersfield, California 93301, United States
  • Allergy & Asthma Medical Group of the Bay Area
    Walnut Creek, California 94598, United States
  • Finlay Medical Research Corporation
    Greenacres City, Florida 33467-2979, United States
  • San Marcus Research Clinic Inc.
    Miami, Florida 33014, United States
  • Oceane7 Medical & Research Center, Inc.
    Miami, Florida 33144-2155, United States
  • Avantis Clinical Research, LLC
    Miami, Florida 33155-3265, United States
  • Research Institute of South Florida Inc
    Miami, Florida 33173, United States
  • Diverse Clinical Research, LLC
    Miami, Florida 33175-3434, United States
  • Central Florida Pulmonary Group, PA
    Orlando, Florida 32803, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - The Villages
    The Villages, Florida 32162-7116, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - Atlanta
    Atlanta, Georgia 30328, United States
  • Allergy Center at Brookstone Research - Centricity Research - HyperCore - PPD
    Columbus, Georgia 31904-2954, United States
  • Pivotal Research Solutions
    Stonecrest, Georgia 30038-2649, United States
  • ASHA Clinical Research - ClinEdge - PPDS
    Hammond, Indiana 46324-2213, United States
  • The Research Group of Lexington, LLC
    Lexington, Kentucky 40504, United States
  • Best Clinical Trials
    New Orleans, Louisiana 70115, United States
  • Paul A. Shapero, MD, PA
    Bangor, Maine 04401-5691, United States
  • Pulmonary Research Institute of Southeast Michigan
    Farmington Hills, Michigan 48336-2817, United States
  • Flushing Road Internal Medicine and Pediatrics - F
    Flint, Michigan 48504-4730, United States
  • Revive Research Institute
    Lathrup Village, Michigan 48076, United States
  • Oakland Medical Research Center
    Troy, Michigan 48085-5524, United States
  • Washington University School of Medicine in St. Louis
    St Louis, Missouri 63110, United States
  • Nebraska Medical Research Institute, Inc. - CRN
    Bellevue, Nebraska 68123-4318, United States
  • Machuca Family Medicine
    Las Vegas, Nevada 89104-3953, United States
  • Renown Regional Medical Center Hospital
    Reno, Nevada 89502-1576, United States
  • Hassman Research Institute - HRI - Berlin - CenExel - PPDS
    Marlton, New Jersey 08053, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - New York
    New York, New York 10017-4008, United States
  • Research Carolina Elite
    Denver, North Carolina 28037-7929, United States
  • Pulmonix LLC
    Greensboro, North Carolina 27403, United States
  • Advanced Respiratory and Sleep Medicine, PLLC
    Huntersville, North Carolina 28078, United States
  • Southeastern Research Center
    Winston-Salem, North Carolina 27103-4029, United States
  • OK Clinical Research
    Edmond, Oklahoma 73034-3258, United States
  • The Oregon Clinic
    Portland, Oregon 97213, United States
  • Clinical Research Associates Of Central Pa , Llc
    Altoona, Pennsylvania 16602, United States
  • Allergy & Clinical Immun Assoc
    Pittsburgh, Pennsylvania 15241, United States
  • Medtrial, LLC
    Columbia, South Carolina 29204, United States
  • Velocity Clinical Research - Gaffney - PPDS
    Gaffney, South Carolina 29340-4737, United States
  • ClinSearch, LLC
    Chattanooga, Tennessee 37421, United States
  • Clinical Trials Center of Middle Tennessee
    Franklin, Tennessee 37067-5603, United States
  • Tennessee Comprehensive Lung & Sleep Center
    Hendersonville, Tennessee 37075-3085, United States
  • TTS Research
    Boerne, Texas 78006, United States
  • Corsicana Medical Research
    Corsicana, Texas 75110-2471, United States
  • Trio Clinical Trials
    Houston, Texas 77008, United States
  • Baylor College of Medicine Medical Center
    Houston, Texas 77030, United States
  • Biopharma Informatic - Park Row - PPDS
    Houston, Texas 77084, United States
  • R & H Clinical Research
    Katy, Texas 77494-2031, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
  • Western Washington Medical Group
    Everett, Washington 98208, United States
  • Allergy Asthma and Sinus Center-Greenfield
    Greenfield, Wisconsin 53228-3467, United States
  • Consultorios Medicos Organizacion de Buen Ayre SRL
    Buenos Aires, 12345, Argentina
  • Nexo Salud Investigacion Clinica - Riobamba 429
    Buenos Aires, C1025, Argentina
  • CINME S.A. ? Centro de Investigaciones Metabolicas - Rx Trials LLC
    Buenos Aires, C1027AAP, Argentina
  • Fundacion Faicep
    Buenos Aires, C1122AAK, Argentina
  • Instituto de Investigaciones En Alergia Y Enfermedades Respiratorias
    Buenos Aires, C1425, Argentina
  • AES - AS - Glenny Corp. S.A. Buenos Aires
    Buenos Aires, C1430, Argentina
  • Centro de Medicina Respiratoria
    Concepción del Uruguay, 3260, Argentina
  • Sanatorio de la Canada
    Córdoba, X5000BSQ, Argentina
  • Framingham Centro Medico
    La Plata, 1900, Argentina
  • Centro Medico Capital
    La Plata, 1904, Argentina
  • Centro Platense en Investigaciones Respiratorias
    La Plata, B1900BNN, Argentina
  • Centro Medico Dharma
    Mendoza, M5500AYB, Argentina
  • Centro Privado de Medicina Respiratoria
    Paraná, 3100, Argentina
  • Sala de primeros auxilios Alberto Mignaburu
    Ranelagh, Berazategui, 1886, Argentina
  • Instituto Medico de la Fundacion Estudios Clinicos
    Rosario, S2000DEJ, Argentina
  • Servicio de Investigacion de Patologias Alergicas-Instituto ABC
    Rosario, S2013JKR, Argentina
  • Sanatorio Parque de Rosario
    Rosario, S2013KZD, Argentina
  • Centro Modelo de Cardiologia
    San Miguel de Tucumán, 4000, Argentina
  • Centro Medico San Nicolas Grupo Orono
    San Nicolás de los Arroyos, B2900, Argentina
  • CEPROSS- Centro Profesional San Salvador
    San Salvador, E3218CHH, Argentina
  • Instituto Del Buen Aire
    Santa Fe, S3000ASF, Argentina
  • Centro de Diagnostico Y Rehabilitacion
    Santa Fe, S3000, Argentina
  • Institute for Respiratory Health - Midland
    Midland, South Australia 6056, Australia
  • Ordination Dr. Robert Voves
    Feldbach, 8330, Austria
  • Ordination fur Lungenkrankheiten
    Linz, 4020, Austria
  • AZ Sint-Jan Brugge-Oostende
    Bruges, 8000, Belgium
  • Universitair Ziekenhuis Brussel
    Brussels, 1090, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • CHU de Liège
    Liège, 4000, Belgium
  • L2IP ?Instituto de Pesquisas Clínicas Ltda.
    Brasília, Federal District 70200-730, Brazil
  • IBPCLIN Instituto Brasil de Pesquisa Clinica
    Rio de Janeiro, Rio de Janeiro 20241-180, Brazil
  • LMK Servicos Medicos SS
    Porto Alegre, Rio Grande do Sul 90480-000, Brazil
  • Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Faculdade de Medicina do ABC - FMABC
    Santo André, São Paulo 09060-650, Brazil
  • CEMEC - Centro Multidisciplinar de Estudos Clínicos
    São Bernardo do Campo, São Paulo 09715-090, Brazil
  • Instituto do Coracao - HCFMUSP
    São Paulo, São Paulo 05403-000, Brazil
  • Diagnostic Consultative Centre Mladost?M OOD
    Varna, Varna 9020, Bulgaria
  • Multiprofile Hospital for Active Treatment Puls AD PPDS
    Blagoevgrad, 2700, Bulgaria
  • Multiprofile Hospital For Active Treatment Sveta Ekaterina - Dimitrovgrad EOOD
    Dimitrovgrad, 6400, Bulgaria
  • Multiprofile Hospital For Active Treatment Dr. Tota Venkova JSC
    Gabrovo, 5300, Bulgaria
  • Medical Center Hera EOOD
    Montana, 3400, Bulgaria
  • Multiprofile Hospital for Active Treatment Plovdiv
    Plovdiv, 4003, Bulgaria
  • Multiprofile Hospital for Active Treatment Sv. Ivan Rilski- Razgrad AD
    Razgrad, 7200, Bulgaria
  • Multiprofile Hospital for Active Treatment Shumen
    Shumen, 9700, Bulgaria
  • Multiprofile Hospital for Active Treatment - Silistra AD
    Silistra, 7500, Bulgaria
  • Multiprofile Hospital For Active Treatment - Dr. Bratan Shukerov AD
    Smolyan, 4700, Bulgaria
  • Fifth Multiprofile Hospital for Active Treatment - Sofia EAD
    Sofia, 1233, Bulgaria

Showing the first 100 of 348 sites across 36 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Papi A, Greening NJ, Bhatt SP, Roche N, Celli B, Wedzicha JA, Agusti A, Tal-Singer R, Han MK, Janssens W, Hanania NA, Nair P, Bremner P, Porpodis K, Shibata Y, Korn S, Yang T, Gordon O, Saenz R, Ng J, Cheung DS, Devine J, Grimbaldeston MA, Zhang W, Yang X, Mohan D, Vogelmeier CF, Brightling CE; ALIENTO and ARNASA investigators. Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials. Lancet. 2026 May 23;407(10543):2027-2039. doi: 10.1016/S0140-6736(26)00637-9. Epub 2026 May 18. PubMed 42150581 ↗
  • Wedzicha JA, Agusti A, Brightling CE, Calverley P, Chalmers JD, Greening NJ, Han MK, Mohan D, Ng J, Papi A, Roche N, Saenz R, Samara K, Tal-Singer R, Vogelmeier CF, Yang X, Celli BR. Astegolimab for COPD With Frequent Exacerbations: Pooled Analysis of the ALIENTO and ARNASA Trials. Am J Respir Crit Care Med. 2026 May 18:aamag226. doi: 10.1093/ajrccm/aamag226. Online ahead of print. PubMed 42148875 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Jun 2025, 29 months.

Results were first posted in Oct 2026, 1 year 4 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 29 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2027 → Aug 2026, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2022
First posted
Oct 27, 2022
StartActual
Dec 29, 2022
Primary completionActual
Jun 24, 2025
CompletionActual
Aug 19, 2026was Sep 2027
Results first posted
Oct 28, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 28, 2026
Results
Results posted
posted Oct 28, 2026
Sites
10 sites added, 44 sites removed
Show 10 added (5 Spain, 2 Brazil, 1 Bulgaria, 1 Canada, 1 Hungary)
  • IBPCLIN Instituto Brasil de Pesquisa Clinica · Rio de Janeiro, Brazil
  • Instituto do Coracao - HCFMUSP · São Paulo, Brazil
  • Diagnostic Consultative Centre Mladost?M OOD · Varna, Bulgaria
  • Centre Hospitalier de l'Universite Laval · Québec, Canada
  • Benyovszky Medical Center · Budapest, Hungary
  • Hospital Universitario La Paz - PPDS · Barcelona, Spain
  • Vithas Xanit International Hospital · Benalmádena Costa, Spain
  • Hospital Universitario Virgen del Rocio · Seville, Spain
  • Hospital Clinico Universitario de Valencia · Valencia, Spain
  • Hospital de La Ribera · Valencia, Spain
Show 44 removed
  • Santa Casa de Misericordia de Belo Horizonte - PPDS · Belo Horizonte, Brazil
  • IBPCLIN Instituto Brasil de Pesquisa Clinica · Rio de Janeiro, Brazil
  • Instituto do Coracao - HCFMUSP · São Paulo, Brazil
  • Diagnostic Consultative Centre Mladost?M OOD · Varna, Bulgaria
  • Centre Hospitalier de l'Universite Laval · Québec, Canada
  • Groupe Hospitalier Cochin St Vincent de Paul La Roche Guyon · Paris, France
  • Benyovszky Medical Center · Budapest, Hungary
  • Makita Hospital · Sapporo, Japan
  • Yokohama Front Clinic · Yokohama, Japan
  • Yokohama-Gumyouji Kokyuukinaika Naika Clinic · Yokohama, Japan
  • Fujieda Municipal General Hospital · Fujieda-Shi, Japan
  • Asahikawa Medical Center · Asahikawa-shi, Japan
  • Fukuoka University Chikushi Hospital · Chikushino-shi, Japan
  • National Hospital Organization Kyushu Medical Center · Chuo-ku, Fukuoka-shi, Japan
  • Fukuoka University Hospital · Fukuoka, Japan
  • Hiroshima Prefectural Hospital · Hiroshima, Japan
  • Ishikawa Prefectural Central Hospital · Ishikawa, Japan
  • National Hospital Organization Minami Kyoto Hospital · Jōyō, Japan
  • Kagoshima Kouseiren Hospital · Kagoshima, Japan
  • Yokohama City University Medical Center · Kanagawa, Japan
  • Osaka-Minami Medical Center · Kawachinagano-Shi, Japan
  • Saiseikai Kumamoto Hospital · Kumamoto, Japan
  • Rakuwakai Otowa Hospital · Kyoto, Japan
  • Machida Municipal Hospital · Machida-shi, Japan
  • Dokkyo Medical University Hospital · Mibu-Machi, Japan
  • Nagoya Ekisaikai Hospital · Nagoya, Japan
  • Niigata City General Hospital · Niigata, Japan
  • Izumi City General Hospital · Osaka, Japan
  • Oita Medical Center · Ōita, Japan
  • National Hospital Organization - Sagamihara National Hospital · Sagamihara-shi Minami-ku, Japan
  • …and 14 more on the registry record
Oct 28, 2026
Study completion
Sep 24, 2027→Aug 19, 2026 (actual)
Oct 28, 2026
Enrollment
1290 (estimated)→1380 (actual)
Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedAnnualized rateRate of moderateModerate and severeSevere COPD exacerbations overExacerbations Over the 52-week treatment periodTreatment PeriodTime frame: 52 weeks → Up to 52 weeks
Oct 28, 2026
Documents
Secondary outcomes
6 edited, 5 added
What changed in the outcomes
  • EditedTime to first moderateFirst Moderate or severeSevere COPD exacerbation duringExacerbation During the 52-week treatment periodTreatment PeriodTime frame: 52 weeks → Up to 52 weeks
  • EditedAbsolute change from baselineChange From Baseline in healthHealth-related quality Quality-of -life (HRQoL) at Week 52, as assessed throughAssessed Through the St.Saint George's Respiratory Questionnaire-COPD (SGRQ-C) total scoreTotal ScoreTime frame: Week 52 → At Week 52
  • EditedAbsolute change from baselineChange From Baseline in postPost-bronchodilator forced expiratory volumeForced Expiratory Volume in 1 Second (FEV1) (Liters) at Week 52Time frame: Week 52 → At Week 52
  • EditedAbsolute change from baselineChange From Baseline in the Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary DiseaseCOPD (E-RS: COPD) total scoreTotal Score at Week 52Time frame: Week 52 → At Week 52
  • EditedProportionPercentage of participants with improvementParticipants With Improvement in HRQoL at Week 52, as Assessed by SGRQ-CTime frame: Week 52 → At Week 52
  • EditedAnnualized rateRate of severeModerate and Severe COPD exacerbations overExacerbations Over the 52-week treatment periodTreatment Period in Participants With Low Baseline Blood Eosinophil Level (<300 Cells Per Microliter [Cells/µL])Time frame: 52 weeks → Up to 52 weeks
  • AddedAnnualized Rate of Severe COPD Exacerbations Over the 52-week Treatment PeriodTime frame: Up to 52 weeks
  • AddedNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Including Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)Time frame: Up to a maximum of 62 weeks
  • AddedNumber of Participants Who Died or Discontinued Study Due to TEAEsTime frame: Up to a maximum of 62 weeks
  • AddedSerum Concentration of AstegolimabTime frame: Up to a maximum of 62 weeks
  • AddedNumber of Participants With Anti-drug Antibodies (ADAs) to AstegolimabTime frame: Up to a maximum of 62 weeks
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Active, not recruiting→Completed
    Results posted
    10 sites added, 44 sites removed
    Show 10 added (5 Spain, 2 Brazil, 1 Bulgaria, 1 Canada, 1 Hungary)
    • IBPCLIN Instituto Brasil de Pesquisa Clinica · Rio de Janeiro, Brazil
    • Instituto do Coracao - HCFMUSP · São Paulo, Brazil
    • Diagnostic Consultative Centre Mladost?M OOD · Varna, Bulgaria
    • Centre Hospitalier de l'Universite Laval · Québec, Canada
    • Benyovszky Medical Center · Budapest, Hungary
    • Hospital Universitario La Paz - PPDS · Barcelona, Spain
    • Vithas Xanit International Hospital · Benalmádena Costa, Spain
    • Hospital Universitario Virgen del Rocio · Seville, Spain
    • Hospital Clinico Universitario de Valencia · Valencia, Spain
    • Hospital de La Ribera · Valencia, Spain
    Show 44 removed
    • Santa Casa de Misericordia de Belo Horizonte - PPDS · Belo Horizonte, Brazil
    • IBPCLIN Instituto Brasil de Pesquisa Clinica · Rio de Janeiro, Brazil
    • Instituto do Coracao - HCFMUSP · São Paulo, Brazil
    • Diagnostic Consultative Centre Mladost?M OOD · Varna, Bulgaria
    • Centre Hospitalier de l'Universite Laval · Québec, Canada
    • Groupe Hospitalier Cochin St Vincent de Paul La Roche Guyon · Paris, France
    • Benyovszky Medical Center · Budapest, Hungary
    • Makita Hospital · Sapporo, Japan
    • Yokohama Front Clinic · Yokohama, Japan
    • Yokohama-Gumyouji Kokyuukinaika Naika Clinic · Yokohama, Japan
    • Fujieda Municipal General Hospital · Fujieda-Shi, Japan
    • Asahikawa Medical Center · Asahikawa-shi, Japan
    • Fukuoka University Chikushi Hospital · Chikushino-shi, Japan
    • National Hospital Organization Kyushu Medical Center · Chuo-ku, Fukuoka-shi, Japan
    • Fukuoka University Hospital · Fukuoka, Japan
    • Hiroshima Prefectural Hospital · Hiroshima, Japan
    • Ishikawa Prefectural Central Hospital · Ishikawa, Japan
    • National Hospital Organization Minami Kyoto Hospital · Jōyō, Japan
    • Kagoshima Kouseiren Hospital · Kagoshima, Japan
    • Yokohama City University Medical Center · Kanagawa, Japan
    • Osaka-Minami Medical Center · Kawachinagano-Shi, Japan
    • Saiseikai Kumamoto Hospital · Kumamoto, Japan
    • Rakuwakai Otowa Hospital · Kyoto, Japan
    • Machida Municipal Hospital · Machida-shi, Japan
    • Dokkyo Medical University Hospital · Mibu-Machi, Japan
    • Nagoya Ekisaikai Hospital · Nagoya, Japan
    • Niigata City General Hospital · Niigata, Japan
    • Izumi City General Hospital · Osaka, Japan
    • Oita Medical Center · Ōita, Japan
    • National Hospital Organization - Sagamihara National Hospital · Sagamihara-shi Minami-ku, Japan
    • …and 14 more on the registry record
    Study completion Sep 24, 2027→Aug 19, 2026 (now actual)
    Enrollment 1290 (estimated)→1380 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedAnnualized rateRate of moderateModerate and severeSevere COPD exacerbations overExacerbations Over the 52-week treatment periodTreatment PeriodTime frame: 52 weeks → Up to 52 weeks
    Secondary outcomes 6 edited, 5 added
    What changed in the outcomes
    • EditedTime to first moderateFirst Moderate or severeSevere COPD exacerbation duringExacerbation During the 52-week treatment periodTreatment PeriodTime frame: 52 weeks → Up to 52 weeks
    • EditedAbsolute change from baselineChange From Baseline in healthHealth-related quality Quality-of -life (HRQoL) at Week 52, as assessed throughAssessed Through the St.Saint George's Respiratory Questionnaire-COPD (SGRQ-C) total scoreTotal ScoreTime frame: Week 52 → At Week 52
    • EditedAbsolute change from baselineChange From Baseline in postPost-bronchodilator forced expiratory volumeForced Expiratory Volume in 1 Second (FEV1) (Liters) at Week 52Time frame: Week 52 → At Week 52
    • EditedAbsolute change from baselineChange From Baseline in the Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary DiseaseCOPD (E-RS: COPD) total scoreTotal Score at Week 52Time frame: Week 52 → At Week 52
    • EditedProportionPercentage of participants with improvementParticipants With Improvement in HRQoL at Week 52, as Assessed by SGRQ-CTime frame: Week 52 → At Week 52
    • EditedAnnualized rateRate of severeModerate and Severe COPD exacerbations overExacerbations Over the 52-week treatment periodTreatment Period in Participants With Low Baseline Blood Eosinophil Level (<300 Cells Per Microliter [Cells/µL])Time frame: 52 weeks → Up to 52 weeks
    • AddedAnnualized Rate of Severe COPD Exacerbations Over the 52-week Treatment PeriodTime frame: Up to 52 weeks
    • AddedNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Including Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)Time frame: Up to a maximum of 62 weeks
    • AddedNumber of Participants Who Died or Discontinued Study Due to TEAEsTime frame: Up to a maximum of 62 weeks
    • AddedSerum Concentration of AstegolimabTime frame: Up to a maximum of 62 weeks
    • AddedNumber of Participants With Anti-drug Antibodies (ADAs) to AstegolimabTime frame: Up to a maximum of 62 weeks
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05595642
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 27, 2022
Start date
Dec 29, 2022
Primary completion
Jun 24, 2025
Completion
Aug 19, 2026
Results posted
Oct 28, 2026
Last update
Oct 28, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Astegolimab

Start the discussion